Anti-Aging Research: Neptune Krill Oil Demonstrates Positive Economic Benefit for Dyslipidemia Treatment

Neptune Technologies & Bioressources Inc. is pleased to announce significantly positive results after the completion of a population-based risk–benefit and a health-economics analysis study for Neptune Krill Oil (NKO™) in the management of dyslipidemia.

The results of the study demonstrate the following:
a. Patients treated with Neptune Krill Oil had significantly reduced risk for cardiovascular events over the next 10 years, by 52%.
b. Patients treated with NKO had a significantly higher chance (-52.3%) to prevent cardiovascular events over the next 10 years when compared to those treated with Fish Oil (-8.9%) or the statin resistant patients treated with low dose statin (83.6%).
c. NKO monotherapy as well as NKO co-administered with a low dose statin was significantly more cost-effective than all other interventions studied for all types of cardiovascular events aggregated.
d. From a cost-benefit perspective NKO remains the most favorable treatment alternative for angina, congestive heart failure, stroke, myocardial infarction, Percutaneous Transluminal Coronary Angioplasty (PTCA), fatal myocardial infarction and coronary artery bypass graft surgery (CABG); NKO has a negative cost-benefit indicating that the cost of acquisition is less than the benefits derived from the intervention.

Read details of this Neptune Krill Oil dyslipidemia economic benefit study.